Oral 1.01: Phase II trial of amrubicin in patients with previously treated advanced thymic malignancies

BACKGROUND: Limited treatment options exist for patients with thymic malignancies (TM), and chemotherapy efficacy is often restricted by cumulative toxicity such as neuropathy (taxanes) and cardiomyopathy (anthracyclines). Single agent amrubicin, a third generation anthracycline and topoisomerase II...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Thorac Dis
Main Authors: Wakelee, Heather A., Padda, Sukhmani K., Burns, Matthew, Spittler, A. J., Riess, Jonathan W., San Pedro-Salcedo, Melanie, Ramchandran, Kavitha J., Gubens, Matthew A., Neal, Joel W., Loehrer, Patrick J.
Formato: Artigo
Idioma:Inglês
Publicado em: AME Publishing Company 2015
Assuntos:
Molecular Biology and Chemotherapy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4700310/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2072-1439.2015.AB054
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados